Tous Actualités
Suivre
Abonner Antisoma plc

Antisoma plc

Results Presented From As1403 Phase I Biodistribution Study

London, UK plc (LSE:ASM, NASD-E:ASOM) (ots)

Antisoma announces
that results from its phase I biodistribution study of AS1403
(formerly TheraFab) will be presented this weekend to the European
Association of Nuclear Medicine meeting in Amsterdam by Dr Michael
Garkavij, a leading investigator in the trial.
AS1403 is a fragment of the monoclonal antibody HMFG1 linked to a
radioactive isotope with cell-killing ability. The biodistribution
study examined the ability of AS1403 to deliver a targeted dose of
radiation to tumours in patients with non-small cell lung cancer. For
this study, the therapeutic isotope in AS1403 was replaced by an
imaging isotope, allowing the investigators to evaluate the
distribution of radioactivity in the body. Imaging showed that
radioactivity accumulated in tumours after administration of AS1403.
This confirms the targeting ability of the antibody fragment, in line
with earlier studies using HMFG1 antibody fragments. However,
dosimetry findings suggested that quantities of radioactivity
delivered to other tissues such as the kidneys could be such that
they would produce unacceptable levels of toxicity if a therapeutic
isotope were used. Significant targeting of the kidneys is a
well-documented property of antibody fragments that is not shared by
whole antibodies. Work to overcome this issue would require
significant investment, and Antisoma has therefore decided not to
continue the development of AS1403 at this time.
Glyn Edwards, CEO of Antisoma, said, 'We have many promising drug
candidates in our pipeline and can therefore move quickly to
discontinue programmes when trial results show that resources would
be more usefully allocated elsewhere.'
Notes to editors
AS1403
AS1403 is a F(ab')2 fragment of the mouse monoclonal antibody
HMFG1 linked to the radioactive isotope yttrium-90. In the phase I
biodistribution study, the yttrium was replaced with the imaging
isotope, indium-111. Previous biodistribution studies on
radiolabelled HMFG1 antibodies include Kalofonos et al. (HMFG1
F(ab')2 fragment; 1988, Cancer Research 48: 1977-1984), Kalofonos et
al. (HMFG1 and HMFG1 F(ab')2 fragment; 1989, Br J Cancer 59: 939-942)
and Al-Yasi et al. (humanised HMFG1; 2002, Br J Cancer 18: 870-878).
This information is provided by RNS The company news service from
the London Stock Exchange

Contact:

Antisoma plc
Glyn Edwards,
Chief Executive Officer
Tel: +44 (0)20 8799 8200

Financial Dynamics
Jonathan Birt
Tel: +44 (0)20 7831 3113